Although there are controversies, chemotherapeutic effectiveness of PARP1 inhibitors have been assessed in BRCA-deficient breast carcinomas [23, 27] and ovarian carcinomas with a BRCA1/2 mutation [26]. The gene discussed is BRCA1; the disease is ovarian carcinoma.